Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

NCT ID: NCT00667563

Last Updated: 2024-03-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2012-11-30

Brief Summary

RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer.

PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well it works in preventing cervical cancer in women in India with HIV-1 infection.

Detailed Description

OBJECTIVES:

Primary

• Assess the safety of the Gardasil® quadrivalent human papillomavirus (HPV) (types 6, 11, 16,18) virus-like-particle vaccine with vs without prior exposure to one or more of the HPV types in the vaccine in HIV-positive women in Chennai, India.
• Determine the effect of the vaccine on HIV viral load and CD4+/CD8+ levels in these patients.
• Determine the proportion of these patients who respond serologically to the HPV vaccine and the kinetics of their response.

Secondary

• Determine the prevalence and incidence of cervical intraepithelial neoplasia in these patients.
• Determine the spectrum of cervical HPV types in these patients at baseline, 9 months, and 1 year after vaccination.

OUTLINE: This is a multicenter study.

Patients receive quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) recombinant vaccine intramuscularly on day 0 and once in weeks 8 and 24.

Patients undergo cervical cell, buccal cell, and blood sample collection at baseline and periodically after vaccination for immunologic and virologic studies. Cervical cytology specimens are examined by polymerase chain reaction to detect HPV 6, 11, 16, or 18 DNA, as well as 35 other HPV types. Blood samples are analyzed for CD4+/CD8+ cell count, plasma HIV-1 RNA levels, and serum HPV antibody titers for HPV types 6, 11, 16, and 18. Some plasma samples will be stored for future HPV pseudovirion neutralization assays.

After completion of study therapy, patients are followed periodically for up to 12 months.

Conditions

Cervical Cancer; Nonneoplastic Condition; Precancerous Condition

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Gardasil Vaccination

Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.

Group Type: EXPERIMENTAL

quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Intervention Type: BIOLOGICAL

Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.

DNA analysis

Intervention Type: GENETIC

Weeks 0, 2, 10, 26, and 52.

polymerase chain reaction

Intervention Type: GENETIC

Screening, week 36, and week 52.

cytology specimen collection procedure

Intervention Type: OTHER

Screening, week 36, and week 52.

colposcopic biopsy

Intervention Type: PROCEDURE

Screening, week 36, and week 52.

Interventions

quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.

Intervention Type: BIOLOGICAL

DNA analysis

Weeks 0, 2, 10, 26, and 52.

Intervention Type: GENETIC

polymerase chain reaction

Screening, week 36, and week 52.

Intervention Type: GENETIC

cytology specimen collection procedure

Screening, week 36, and week 52.

Intervention Type: OTHER

colposcopic biopsy

Screening, week 36, and week 52.

Intervention Type: PROCEDURE

Other Intervention Names

HIV viral load test and HPV neutralization assays.

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western blot before study entry

• HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
• Meets 1 of the following criteria:

• Nadir CD4 level of ≤ 350 cells/mm³ and receiving highly active antiretroviral therapy (HAART) for at least 6 months before study entry
• Nadir CD4 level of > 350 cells/mm³ and not receiving HAART at the time of study entry
• No known history of high-grade CIN or cervical cancer

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• ANC > 750 cells/mm³
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100,000/mm³
• Serum creatinine ≤ 3 times upper limit of normal (ULN)
• AST and ALT ≤ 3.0 times ULN
• Conjugated (direct) bilirubin ≤ 2.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the site Investigator
• No serious illness requiring systemic treatment and/or hospitalization within the past 45 days
• No allergy to yeast or any of the components of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• More than 45 days since prior systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin

• Routine standard of care, including hepatitis B, influenza, and tetanus vaccines are allowed

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

The Emmes Company, LLC

INDUSTRY

Sponsor Role: collaborator

AIDS Malignancy Consortium

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joel Palefsky, MD

Role: STUDY_CHAIR

University of California, San Francisco

N. Kumarasamy, MD

Role: PRINCIPAL_INVESTIGATOR

YRG Care

Locations

YRG Care

Chennai, , India

Countries

India

Related Links

https://clinicaltrials.gov/study/NCT00667563

Clinical trial summary for AMC-054

Other Identifiers

U01CA121947

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CDR0000593634

Identifier Type: OTHER

Identifier Source: secondary_id

AMC-054

Identifier Type: -

Identifier Source: org_study_id